TROPION-Lung01 Study Design and Baseline demographics
Daiichi-Sankyo
•
•
Background: Dato-DXd
Dato-DXd is a TROP2-directed ADC, that selectively
delivers a potent Topo-l inhibitor payload directly into
tumor cells, 1 and has several unique properties*:
-
- Optimised drug to antibody ratio ≈ 4
Stable linker-payload
Tumour-selective cleavable linker
- Bystander antitumour effect
Dato-DXd previously demonstrated promising
antitumour activity and a manageable safety profile
with a convenient Q3W schedule in pre-treated patients
with metastatic HR+/HER2- breast cancer²
*The clinical relevance of these features is under investigation. Based on animal data.
Dato-DXd, datopotamab deruxtecan; IgG1, immunoglobulin G1; Q3W, every 3 weeks; Topo-1, topisomerase I.
Dato-DXd: Humanised anti-TROP2 IgG1
monoclonal antibody
0
Deruxtecan
H
H
"NH
H
H₂C.
HO
-CH3
Cleavable
tetrapeptide-based linker
Topo-l inhibitor payload
(DXd)
Image is for illustrative purposes only; actual drug positions may vary.
1. Okajima D, et al. Mol Cancer Ther 2021;20:2329-40;
2. Meric-Bernstam F, et al. Poster presentation at SABCS 2022: abstract PD13-08.
25View entire presentation